- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|Scientists are developing a new form of aspirin to overcome “aspirin resistance,” which affects millions of people who could otherwise benefit from the drug commonly used to prevent heart attack and stroke.|
Scientists are reporting development of a new form of aspirin — taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke — that could extend aspirin's benefits to people who may not respond to the drug. Their advance toward coping with "aspirin resistance" appears in the journal ACS Nano.
Shiqi Peng, Ming Zhao and colleagues note that aspirin lowers cardiovascular disease risk by keeping blood cells called platelets from clumping and forming clots. But some experts believe that aspirin doesn't work for millions of people, who may switch to more costly, potent prescription drugs with more serious side effects. Scientists have tried to address aspirin resistance by combining it with other drugs. But Peng and Zhao say that the problem remains. Their research group decided to modify aspirin in an effort to make it work for more people.
They linked aspirin to a carrier consisting of a fragment of protein that can transport aspirin directly to damaged parts of blood vessels where clots form. Experiments with laboratory rats, stand-ins for humans in such early tests, showed that the carrier delivered aspirin to areas of blood vessels where clots were forming. It released aspirin inside the developing clot and stopped the clot-formation process.
The authors acknowledge funding from the Engineering Research Center of Endogenous Prophylactic of the Ministry of Education of the People's Republic of China, PHR (IHLB), the National Natural Science Foundation and the Beijing Natural Science Foundation and Special Project of China.
About American Chemical Society
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 163,000 members, ACS is the world’s largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
For more information, please click here
Ming Zhao, Ph.D.
College of Pharmaceutical Sciences
Capital Medical University
People’s Republic of China
Katie Cottingham, Ph.D.
Copyright © American Chemical SocietyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers